We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · July 28, 2020

TriMixDC-MEL as Adjuvant Treatment for Stage III/IV Disease-Free Melanoma Patients Following the Resection of Macrometastases

Cancer Immunology, Immunotherapy: CII


Additional Info

Cancer Immunology, Immunotherapy: CII
A Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Monocyte-Derived Dendritic Cells (TriMixDC-MEL) as Adjuvant Treatment for Stage III/IV Melanoma Patients Who Are Disease-Free Following the Resection of Macrometastases
Cancer Immunol. Immunother. 2020 Jun 26;[EPub Ahead of Print], Y Jansen, V Kruse, J Corthals, K Schats, PJ van Dam, T Seremet, C Heirman, L Brochez, M Kockx, K Thielemans, B Neyns

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading